about
Treatment of light chain deposition disease with bortezomib and dexamethasoneWaldenström's macroglobulinemia: a clinical perspective in the era of novel therapeuticsDiscovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration AnalysisBET bromodomain inhibition as a therapeutic strategy to target c-MycValidation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH)The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimensSomatic mutations of adenomatous polyposis coli gene and nuclear b-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt pathway implicationRecent Data Supporting Novel Management Strategies for Patients With Multiple Myeloma.Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group.The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group.Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.Proteasome inhibitor associated thrombotic microangiopathy.Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myelomaConservative treatment of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patientsCentral nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensusInternational Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome.Pathogenesis and treatment of renal failure in multiple myeloma.VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA sTreatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone.High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents.Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells.European Myeloma Network guidelines for the management of multiple myeloma-related complications.Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo stagingIncreased angiogenesis and enhanced bone formation in patients with IgM monoclonal gammopathy and urticarial skin rash: new insight into the biology of Schnitzler syndrome.Hematological malignancies: myeloma.The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.The evolving role of lenalidomide in the treatment of hematologic malignancies.Economic evaluation of therapies for patients suffering from relapsed-refractory multiple myeloma in Greece.Management of relapsed and relapsed refractory myeloma.Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens.Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration.Treatment of plasma cell dyscrasias with lenalidomide.The role of novel drugs in multiple myeloma.Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma.Targeted therapies in multiple myeloma.
P50
Q24658325-9C5020F4-DA27-4715-9C61-A6240ADE20D7Q26776391-73F4DC81-F4ED-466C-B5F0-A49855AAFEE4Q27728041-A28BA8F0-E7C6-4FDA-AD77-A9821DB28DA0Q28247024-49EED5BC-B3C6-44B1-9B06-45546C3BC9FBQ28281536-1EE45D59-5908-4E32-87BF-92B4A076C11FQ28287804-97D6078D-7CA7-485B-84C9-F0D508877577Q28296419-D7997AD5-6F9C-4112-9EDD-9326357C3047Q31126101-B5782739-7BB9-4BCF-ADD0-EC4B3265850CQ33365650-6BE4D82D-6CE7-479E-B735-1A5D61CD6BFDQ33369533-81102DE8-6BA3-4100-89D1-B3BB4E3217E9Q33398587-BE4E1C8D-97B9-4290-930E-A383E8E6B22AQ33432949-761FCC5F-020C-4000-BA2C-5A3CD7D1500FQ33437577-97F12EA1-CB92-45F2-98C5-049B19A47C5BQ33573752-97A853E1-5FDB-4D52-A4E7-E7FF596A443BQ33865551-6340F3EF-EEB6-4141-967E-56B09C86518EQ33885555-F36D0C29-66E5-49C9-A05E-628B729ADF54Q34106817-E52648D4-C052-4282-9A18-25F84A1D6FBDQ34450381-353E7FE9-64CB-49AB-9504-F2F23A538A60Q34542980-130A6F27-2806-4BE5-9F21-003A2E2DAD45Q34592826-4E113AA4-A0C1-4064-B7E5-DCBBF6C06F93Q34613164-4D63B2EF-389D-4C8E-AF4F-C525F4C8F73BQ34714894-B21C453D-40B4-4308-B306-6FDFA39614AEQ35005245-2EE53F49-7C5C-4916-9ED5-5B130732572AQ35552719-DC932655-D60A-44CF-9B46-5D6732577248Q36115636-83B0C027-C43D-4580-8646-E0FB36EC6BFEQ36288753-37D3D7FD-BED6-4C8A-A6A6-2DFEC6F75454Q36366608-D1E82EEE-8A56-4C3B-B630-5E8474AAD6B5Q36612641-6A3B1150-2992-472A-846F-042A2001A62EQ36673465-AD5E6097-BDBD-4792-8085-ADA23EDA7011Q36739807-0073EE95-A297-468E-AF73-191AD2883030Q36768997-A5A2B724-144D-4192-BECA-1A709C93FBEEQ36998228-BCD8C42A-3C82-4A56-8ECD-4EEE5344D6A4Q37112901-9F87C349-1E2C-4672-B006-9A12F7F78146Q37157442-EC9E0F88-BA37-44A0-BE3C-AB8A47DC8EBEQ37175616-B956C5AD-CCE3-4A55-8F25-F0681E980EF0Q37176044-9AD77FF6-A4D1-4F43-A90E-82D5C04374E3Q37268527-A51404E5-CB2A-42C4-A862-8D890A51DA9CQ37338703-E02CFA6A-7456-4221-804B-D41D1206E214Q37397495-BE82033B-F4EF-4443-86A2-757B3C888875Q37431609-607DA40C-5360-42BA-AF03-CE3C5564568F
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Efstathios Kastritis
@ast
Efstathios Kastritis
@en
Efstathios Kastritis
@es
Efstathios Kastritis
@nl
Efstathios Kastritis
@sl
type
label
Efstathios Kastritis
@ast
Efstathios Kastritis
@en
Efstathios Kastritis
@es
Efstathios Kastritis
@nl
Efstathios Kastritis
@sl
prefLabel
Efstathios Kastritis
@ast
Efstathios Kastritis
@en
Efstathios Kastritis
@es
Efstathios Kastritis
@nl
Efstathios Kastritis
@sl
P106
P1153
8504977900
P21
P31
P496
0000-0001-8191-5832